Literature DB >> 11502542

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.

J Capilla1, M Ortoneda, F J Pastor, J Guarro.   

Abstract

We used a modified reference microdilution method (the M-38P method) to evaluate the in vitro activities of the new triazole UR-9825 in comparison with those of amphotericin B against 77 strains of opportunistic filamentous fungi. UR-9825 was clearly more active than amphotericin B against all fungi except Fusarium solani and Scytalidium spp. Notably, UR-9825 had low MICs for Aspergillus fumigatus and Paecilomyces lilacinus (MICs at which 90% of isolates are inhibited, 0.125 microg/ml for both species).

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11502542      PMCID： PMC90705          DOI： 10.1128/AAC.45.9.2635-2637.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections.

Authors:  L G Castro; A Salebian; M N Sotto
Journal:  J Med Vet Mycol       Date:  1990

2.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi.

Authors:  I Pujol; J Guarro; C Llop; L Soler; J Fernández-Ballart
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.

Authors:  G Ramos; M Cuenca-Estrella; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

4.  Opportunistic mycotic infection caused by Chaetomium in a patient with acute leukemia.

Authors:  E C Hoppin; E L McCoy; M G Rinaldi
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

Review 5.  Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management.

Authors:  S E Vartivarian; E J Anaissie; G P Bodey
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

Review 6.  Paecilomyces sinusitis in an immunocompromised adult patient: case report and review.

Authors:  R Gucalp; P Carlisle; P Gialanella; S Mitsudo; J McKitrick; J Dutcher
Journal:  Clin Infect Dis       Date:  1996-08       Impact factor: 9.079

7.  Pathogenicity and antifungal susceptibility of Chaetomium species.

Authors:  J Guarro; L Soler; M G Rinaldi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

8.  Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome.

Authors:  V A Morrison; R J Haake; D J Weisdorf
Journal:  Am J Med       Date:  1994-06       Impact factor: 4.965

9.  Onychomycosis caused by Chaetomium globosum Kunze.

Authors:  J Naidu; S M Singh; M Pouranik
Journal:  Mycopathologia       Date:  1991-01       Impact factor: 2.574

Review 10.  Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: case report and review.

Authors:  F Westenfeld; W K Alston; W C Winn
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948
View more
  8 in total

1.  Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex.

Authors:  Mónica Azor; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization.

Authors:  Carolina Serena; Montserrat Ortoneda; Javier Capilla; F Javier Pastor; Deanna A Sutton; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

3.  Efficacy of albaconazole against Candida albicans in a vaginitis model.

Authors:  Gloria M González; Efrén Robledo; Elvira Garza-González; Mariana Elizondo; J Gerardo González
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

4.  Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.

Authors:  Javier Capilla; Clara Yustes; Emili Mayayo; Belkys Fernández; Montserrat Ortoneda; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.

Authors:  Margarita Garau; Manolo Pereiro; Amalia del Palacio
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  In vitro interactions of approved and novel drugs against Paecilomyces spp.

Authors:  Montserrat Ortoneda; Javier Capilla; F Javier Pastor; Isabel Pujol; Clara Yustes; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

7.  In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.

Authors:  Abdalla O A Ahmed; Wendy W J van de Sande; Wim van Vianen; Alex van Belkum; Ahmed H Fahal; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 8.  Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.

Authors:  Julie Autmizguine; Jeffrey T Guptill; Michael Cohen-Wolkowiez; Daniel K Benjamin; Edmund V Capparelli
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.